Increasing competition in recombinant antibody and protein drug discovery has resulted from the U.S. Patent Office instituting 'First to File'. As a result, the time frame for generating patentable biologic molecules has been extremely compressed. Companies are now forced to utilize methods that can significantly speed transient hits through to stable pools and clones. Thomson Instrument Company and MaxCyte will show new methodology to produce scalable recombinant antibodies and proteins that will lead to faster and higher titers with excellent glycosylation. Our technical advancements in shake flask design, and improvements in transfection significantly shorten timelines and improve product quality allowing for faster filing.